Start › Rak jelita grubego i odbytnicy › Karolina Północna › Durham
Badania kliniczne dla Rak jelita grubego i odbytnicy w mieście Durham, NC
28 badań dla Rak jelita grubego i odbytnicy szuka uczestników w ośrodkach w mieście Durham i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekrutacjaZapraszamy zdrowych ochotników
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi dalej
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
RekrutacjaFaza 3
- Duke University Medical Center /ID# 279322, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- Durham VA Medical Center, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekrutacjaFaza 1
- Exelixis Clinical Site #12, Durham
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RekrutacjaFaza 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RekrutacjaFaza 1/2
- Duke Cancer Center, Durham
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RekrutacjaFaza 2
- University of North Carolina Medical Center /ID# 267786, Chapel Hill · 10 mi dalej
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
RekrutacjaFaza 3
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi dalej
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
RekrutacjaFaza 3
- Duke University Medical Center, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekrutacjaFaza 1
- Duke University Medical Center, Durham
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RekrutacjaFaza 1/2
- Duke University Medical Center, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekrutacjaFaza 1/2
- Duke University School of Medicine, Durham
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
RekrutacjaFaza 3
- The University of North Carolina At Chapel Hill, Chapel Hill · 10 mi dalej
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
RekrutacjaFaza 3
- Duke Cancer Center, Durham
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RekrutacjaFaza 1
- Duke University Medical Center, Durham
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
RekrutacjaFaza 2
- Duke University Medical Center - Duke Cancer Center, Durham
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Duke University, Durham
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
RekrutacjaFaza 1/2
- GSK Investigational Site, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1
- Duke Cancer Center, Durham
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
RekrutacjaFaza 3
- Duke University Hospital, Durham
- Duke University Medical Center, Duke Cancer Center, Durham
- Duke University Medical Center, Durham
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
RekrutacjaFaza 2
- Duke University Medical Center, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Rekrutacja
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi dalej
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RekrutacjaFaza 2
- Duke University Medical Center /ID# 279457, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RekrutacjaFaza 1
- Research Site, Durham
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RekrutacjaFaza 1/2
- Duke University Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RekrutacjaFaza 1
- Duke Cancer Center, Durham
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Rekrutacja
- Duke Cancer Institute, Durham
Badania dla Rak jelita grubego i odbytnicy w innych miastach
- Houston, TX102 badań
- New York City, NY78 badań
- Nashville, TN69 badań
- Boston, MA63 badań
- Los Angeles, CA59 badań
- Arlington, VA52 badań
- St. Louis, MO50 badań
- San Antonio, TX46 badań
- Philadelphia, PA44 badań
- Grand Rapids, MI40 badań
- Baldwin Park, CA37 badań
- Chicago, IL34 badań
Inne badania w mieście Durham
- Rak piersi64 badań
- Nowotwory (wszystkie typy)58 badań
- Niedrobnokomórkowy rak płuca39 badań
- Szpiczak mnogi37 badań
- Ostra białaczka szpikowa33 badań
- Nowotwór przerzutowy33 badań
- Rak prostaty32 badań
- Rak płuc32 badań
- Rak jajnika27 badań
- Przewlekła białaczka limfocytowa27 badań
- Niewydolność serca26 badań
- Rak trzustki24 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.